IntraLase IPO raises $87M for future growth

Irvine, CA-IntraLase Corp. glided into the public realm in early October with a successful initial public offering (IPO) at the top of its indicated range, selling nearly 7.3 million shares and raising $86.6 million.

Related Videos
Related Content

FDA apporoves twice-daily dosing option for presbyopia eye drop treatment

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Lotilaner ophthalmic solution an effective, safe treatment for Demodex blepharitis

March 30th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

FDA apporoves twice-daily dosing option for presbyopia eye drop treatment

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Lotilaner ophthalmic solution an effective, safe treatment for Demodex blepharitis

March 30th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

FDA apporoves twice-daily dosing option for presbyopia eye drop treatment

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Lotilaner ophthalmic solution an effective, safe treatment for Demodex blepharitis

March 30th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023
© 2023 MJH Life Sciences

All rights reserved.